JOHN W. HADDEN II

John has extensive experience shaping and executing strategy, building strong partnerships, managing transformational change and leading genuinely diverse organizations.  

He co-founded IRX Therapeutics, an immuno-oncology platform company, where he held roles of increasing responsibility, including CFO, COO and CEO. As CEO, he led the closing of a strategic transaction with Celgene Corporation. In addition to hands-on executive roles, John has provided support and insight to leadership teams on issues including product investments and financing strategy, as well as broader operational and commercial matters.

He has held leadership or senior advisory roles at Secura Bio, King’s Health Partners’ Hematology Institute, Disruptive Capital, OS Therapies, PLx Pharma, and IRX Therapeutics. 

John’s early career was spent as an Investment banker and venture capital investor at JP Morgan & Co, Inc. He earned his MBA from the Harvard University Graduate School of Business Administration and earned his BS in Management, summa cum laude, from Tulane University.